A pan-cancer study identified 56 local cellular programs and 13 spatial niches across 12 cancer types. Multiple niches were linked to prognosis, immunotherapy response, and macrophage spatial distribution.
Studies in muscle-invasive bladder cancer found ctDNA predicted metastatic risk after bladder-sparing treatment, while urine tumor DNA was more sensitive for residual bladder disease. Data from RETAIN-2 and a PNAS study support molecular testing to help select patients for bladder preservation.
New data from 1,868 SEER-linked patients showed DecisionDx-Melanoma identified significant five-year survival differences within the same AJCC stage. The findings were presented at the 2026 AAD Annual Meeting.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07562581 |
A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC |
NOT_YET_RECRUITING | PHASE2 |
| NCT06884839 |
Tumor Deposits in Colorectal Cancer and Its Prognostic Value in Survival and Metastasis |
COMPLETED | |
| NCT06863272 |
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) |
RECRUITING | PHASE1/PHASE2 |
| NCT04261777 |
Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients |
TERMINATED | PHASE3 |
| NCT03644303 |
Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients. |
COMPLETED | NA |
